Clinical reference Biomarker Directory
Back to directory

Creatine Kinase

Established

CK is a muscle injury marker, now mainly used for rhabdomyolysis and statin myopathy rather than heart attack diagnosis.

Also known as CK CPK creatine phosphokinase
In plain language

Creatine kinase rises when muscle is damaged. It used to be a main heart attack test but has mostly been replaced by troponin. Today, it's most useful for catching severe muscle breakdown (rhabdomyolysis) or muscle side effects from cholesterol medications.

Biomarker & context

Creatine kinase (CK) is an enzyme found in heart, skeletal muscle, and brain tissue that catalyzes energy transfer reactions; elevated blood levels indicate muscle or cardiac cell damage.

What it indicates

CK elevation signals muscle injury from various causes, most notably rhabdomyolysis (severe muscle breakdown) and statin-associated muscle symptoms; its cardiac-specific isoenzyme (CK-MB) was historically used to diagnose heart attacks.

Diagnosis & clinical testing

CK-MB's cardiac-marker role has been almost entirely superseded by troponin, which is more sensitive and specific for myocardial injury — CK-MB is now mainly a secondary or historical marker rather than first-line for heart attack diagnosis.

Guiding treatment

Where CK genuinely remains first-line: monitoring for statin-associated muscle symptoms and diagnosing rhabdomyolysis, where markedly elevated CK (often more than 10x the upper limit of normal) is a key diagnostic threshold guiding aggressive fluid resuscitation to prevent kidney injury.

Clinical significance

CK-MB's cardiac role has been superseded by troponin, which is more sensitive and specific.

References
  1. General cardiology and clinical chemistry literature on troponin superseding CK-MB in acute coronary syndrome diagnosis.